Back

Latest Forum Topics / EFH Ltd    Last:0.045    -0.001

Post Reply

BIO PHARMA company do research on MEDICAL DISEASES Post Reply Rate topic
WBdisciple Elite	14-Jul-2020 22:54        WBdisciple About Contact  Quote this Post!
x 0   x 0  Alert Admin	Interesting...The Company aims to develop new serology tests which incorporate the Technology.
Useful To Me  Not Useful To Me
guards80 Supreme	14-Jul-2020 22:53        guards80 About Contact  Quote this Post!
x 0   x 0  Alert Admin	cfm good. Tmr help push up sed medtecs ug and riverstone liaoz gregtan123      ( Date: 14-Jul-2020 22:51) Posted: Not vested but sounds SUPER GOOD? 1 SGD? WBdisciple      ( Date: 14-Jul-2020 22:50) Posted: https://links.sgx.com/FileOpen/Announcement%20for%20Accelerate%20_Final.ashx?App=Announcement& FileID=623696 The board of directors (the " Board" or &ldquo Directors&rdquo ) of Biolidics Limited (the &ldquo Company&rdquo and, together with its subsidiaries, the &ldquo Group&rdquo ) is pleased to announce that the Company had, on 9 July 2020, entered into a licensing agreement (the " Agreement" ) with Accelerate Technologies Pte Ltd (&ldquo A*ccelerate&rdquo ) for a duration of five years from the date of the Agreement (the &ldquo Term&rdquo ). For additional information, please visit https://www.a-star.edu.sg/accelerate. Pursuant to the Agreement, A*ccelerate has granted the Company non-exclusive worldwide rights to (1) use the technology for the detection of COVID-19 viral spike/Angiotensin Converting Enzyme 2 (&ldquo ACE2&rdquo ) blocking antibodies (the &ldquo Technology&rdquo ) for diagnostic use for the Term to further develop the Technology, and (2) market the serology tests which incorporate the Technology. The Company aims to develop new serology tests which incorporate the Technology. Most commercially available serology tests against COVID-19, including the Company&rsquo s COVID-19 Antibody Test Kit launched on 30 March 2020, detects the IgG and IgM antibodies (a group of antibodies produced by the body in response to the infection of SARS-CoV-2 virus). As such, these serology tests which detect the presence of IgG and IgM are currently used only as an assistive tool in the detection of COVID-19, and they are not able to detect specific antibodies that bind to the SARS-CoV-2 virus which interfere with its ability to infect target cells. Serology tests which incorporate the Technology allow the detection of such COVID-19 viral spike/ ACE2 blocking antibodies which may interfere with the ability of the virus to infect the target cells and may provide indication of protective immunity against COVID-19. However, it is important to note that there is currently little information on the level of antibodies sufficient to confer protective immunity to an individual and how long such protective immunity against COVID-19 may last in an individual. The Agreement is not expected to have a material impact on the earnings per share and the net asset value of the Group for the current financial year ending 31 December 2020. Shareholders and potential investors should note that policies in relation to diagnosis and/or detection of the COVID-19 virus and/or antibodies in various jurisdictions may change in response to developments in the COVID-19 situation, which is evolving rapidly. Further, there is no certainty that the Group will be able to successfully commercialise the serology tests which incorporate the Technology, if developed. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take. Save for their respective shareholdings in the Company (if any), the Company is not aware of any of its Directors or substantial shareholders of the Company having any interest, direct or indirect in the Agreement.
Useful To Me  Not Useful To Me
gregtan123 Supreme	14-Jul-2020 22:51        gregtan123 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Not vested but sounds SUPER GOOD? 1 SGD? WBdisciple      ( Date: 14-Jul-2020 22:50) Posted: https://links.sgx.com/FileOpen/Announcement%20for%20Accelerate%20_Final.ashx?App=Announcement& FileID=623696 The board of directors (the " Board" or &ldquo Directors&rdquo ) of Biolidics Limited (the &ldquo Company&rdquo and, together with its subsidiaries, the &ldquo Group&rdquo ) is pleased to announce that the Company had, on 9 July 2020, entered into a licensing agreement (the " Agreement" ) with Accelerate Technologies Pte Ltd (&ldquo A*ccelerate&rdquo ) for a duration of five years from the date of the Agreement (the &ldquo Term&rdquo ). For additional information, please visit https://www.a-star.edu.sg/accelerate. Pursuant to the Agreement, A*ccelerate has granted the Company non-exclusive worldwide rights to (1) use the technology for the detection of COVID-19 viral spike/Angiotensin Converting Enzyme 2 (&ldquo ACE2&rdquo ) blocking antibodies (the &ldquo Technology&rdquo ) for diagnostic use for the Term to further develop the Technology, and (2) market the serology tests which incorporate the Technology. The Company aims to develop new serology tests which incorporate the Technology. Most commercially available serology tests against COVID-19, including the Company&rsquo s COVID-19 Antibody Test Kit launched on 30 March 2020, detects the IgG and IgM antibodies (a group of antibodies produced by the body in response to the infection of SARS-CoV-2 virus). As such, these serology tests which detect the presence of IgG and IgM are currently used only as an assistive tool in the detection of COVID-19, and they are not able to detect specific antibodies that bind to the SARS-CoV-2 virus which interfere with its ability to infect target cells. Serology tests which incorporate the Technology allow the detection of such COVID-19 viral spike/ ACE2 blocking antibodies which may interfere with the ability of the virus to infect the target cells and may provide indication of protective immunity against COVID-19. However, it is important to note that there is currently little information on the level of antibodies sufficient to confer protective immunity to an individual and how long such protective immunity against COVID-19 may last in an individual. The Agreement is not expected to have a material impact on the earnings per share and the net asset value of the Group for the current financial year ending 31 December 2020. Shareholders and potential investors should note that policies in relation to diagnosis and/or detection of the COVID-19 virus and/or antibodies in various jurisdictions may change in response to developments in the COVID-19 situation, which is evolving rapidly. Further, there is no certainty that the Group will be able to successfully commercialise the serology tests which incorporate the Technology, if developed. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take. Save for their respective shareholdings in the Company (if any), the Company is not aware of any of its Directors or substantial shareholders of the Company having any interest, direct or indirect in the Agreement.
Useful To Me  Not Useful To Me
Superfast Supreme	14-Jul-2020 22:50        Superfast About Contact  Quote this Post!
x 0   x 0  Alert Admin	They get a 5 yrs contract
Useful To Me  Not Useful To Me
WBdisciple Elite	14-Jul-2020 22:50        WBdisciple About Contact  Quote this Post!
x 0   x 0  Alert Admin	https://links.sgx.com/FileOpen/Announcement%20for%20Accelerate%20_Final.ashx?App=Announcement& FileID=623696 The board of directors (the " Board" or &ldquo Directors&rdquo ) of Biolidics Limited (the &ldquo Company&rdquo and, together with its subsidiaries, the &ldquo Group&rdquo ) is pleased to announce that the Company had, on 9 July 2020, entered into a licensing agreement (the " Agreement" ) with Accelerate Technologies Pte Ltd (&ldquo A*ccelerate&rdquo ) for a duration of five years from the date of the Agreement (the &ldquo Term&rdquo ). For additional information, please visit https://www.a-star.edu.sg/accelerate. Pursuant to the Agreement, A*ccelerate has granted the Company non-exclusive worldwide rights to (1) use the technology for the detection of COVID-19 viral spike/Angiotensin Converting Enzyme 2 (&ldquo ACE2&rdquo ) blocking antibodies (the &ldquo Technology&rdquo ) for diagnostic use for the Term to further develop the Technology, and (2) market the serology tests which incorporate the Technology. The Company aims to develop new serology tests which incorporate the Technology. Most commercially available serology tests against COVID-19, including the Company&rsquo s COVID-19 Antibody Test Kit launched on 30 March 2020, detects the IgG and IgM antibodies (a group of antibodies produced by the body in response to the infection of SARS-CoV-2 virus). As such, these serology tests which detect the presence of IgG and IgM are currently used only as an assistive tool in the detection of COVID-19, and they are not able to detect specific antibodies that bind to the SARS-CoV-2 virus which interfere with its ability to infect target cells. Serology tests which incorporate the Technology allow the detection of such COVID-19 viral spike/ ACE2 blocking antibodies which may interfere with the ability of the virus to infect the target cells and may provide indication of protective immunity against COVID-19. However, it is important to note that there is currently little information on the level of antibodies sufficient to confer protective immunity to an individual and how long such protective immunity against COVID-19 may last in an individual. The Agreement is not expected to have a material impact on the earnings per share and the net asset value of the Group for the current financial year ending 31 December 2020. Shareholders and potential investors should note that policies in relation to diagnosis and/or detection of the COVID-19 virus and/or antibodies in various jurisdictions may change in response to developments in the COVID-19 situation, which is evolving rapidly. Further, there is no certainty that the Group will be able to successfully commercialise the serology tests which incorporate the Technology, if developed. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take. Save for their respective shareholdings in the Company (if any), the Company is not aware of any of its Directors or substantial shareholders of the Company having any interest, direct or indirect in the Agreement.
Useful To Me  Not Useful To Me
Casilb Master	14-Jul-2020 22:50        Casilb About Contact  Quote this Post!
x 0   x 0  Alert Admin	Finally something out..
Useful To Me  Not Useful To Me
gregtan123 Supreme	14-Jul-2020 22:48        gregtan123 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Biolidics SUPER GOOD ANNOUCEMENT?
Useful To Me  Not Useful To Me
wenyen Master	14-Jul-2020 22:47        wenyen About Contact  Quote this Post!
x 0   x 0  Alert Admin	4) The trading halt cannot exceed 3 market days or such short extension as the Exchange agrees. (5) A trading halt may be changed to a suspension by the Exchange at any time.
Useful To Me  Not Useful To Me
Lailai888 Member	14-Jul-2020 22:31        Lailai888 About Contact  Quote this Post!
x 0   x 0  Alert Admin	On 8 July 2020, Biolidics announced that it has entered into a strategic partnership with LC-Bio to develop cancer-diagnostic solutions. The partnership was not new and there had been an earlier announcement back in Feb 2020 between the Biolidics and LC-Bio tie-up. See this link  https://news.tianyancha.com/ll_rv2l6p8uq3.html If you were to dig deeper, LC-Bio had just completed a series B funding of approximately RMB100 or SGD20 million.  http://www.lc-bio.com/news/show-715.html Could the halting of Biolidics be related to this series B funding? A potential take-over by LC-Bio? Or a discussion with Biolidics on how to utilitze the funds?  I' m not an insider but I' m vested. The information above are sourced through the public domain and represents my own personal view.
Useful To Me  Not Useful To Me
eric998 Supreme	14-Jul-2020 22:28        eric998 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Hope don?t suspend ahhuat08      ( Date: 14-Jul-2020 21:28) Posted: trading halt +3 which is latest by thursday they need to unhalt or else suspension. Trader130      ( Date: 14-Jul-2020 20:51) Posted: Tomor last day .. Finger crosssed
Useful To Me  Not Useful To Me
WBdisciple Elite	14-Jul-2020 22:24        WBdisciple About Contact  Quote this Post!
x 0   x 0  Alert Admin	If you have no basis of such info, please refrain from such frivolous  comments nott1965      ( Date: 14-Jul-2020 19:47) Posted: Rights issue as company almost bankrupt liao?
Useful To Me  Not Useful To Me
tccy73 Senior	14-Jul-2020 21:45        tccy73 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Err, sembmarine?😅 Sgvale      ( Date: 14-Jul-2020 21:31) Posted: Development in the counter is pointing positively prior halting. 2-3 days ago trading volume see big increase together will the price rises. Somemore closed near peak before halt. Is that the normal signs for those previous halted counters pending announcement with bad news?
Useful To Me  Not Useful To Me
Trader130 Supreme	14-Jul-2020 21:44        Trader130 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Wind sound zhun bueh ? 😅 not_me      ( Date: 14-Jul-2020 21:21) Posted: U have wind sound? easywin      ( Date: 14-Jul-2020 21:20) Posted: I think we shall hear some good news tomorrow morning before market reopens
Useful To Me  Not Useful To Me
Sgvale Supreme	14-Jul-2020 21:31        Sgvale About Contact  Quote this Post!
x 0   x 0  Alert Admin	Development in the counter is pointing positively prior halting. 2-3 days ago trading volume see big increase together will the price rises. Somemore closed near peak before halt. Is that the normal signs for those previous halted counters pending announcement with bad news?
Useful To Me  Not Useful To Me
ahhuat08 Elite	14-Jul-2020 21:28        ahhuat08 About Contact  Quote this Post!
x 0   x 0  Alert Admin	trading halt +3 which is latest by thursday they need to unhalt or else suspension. Trader130      ( Date: 14-Jul-2020 20:51) Posted: Tomor last day .. Finger crosssed  ST3-trading      ( Date: 14-Jul-2020 20:47) Posted: so they left one more day to announce . tml is 3rd day ?
Useful To Me  Not Useful To Me
not_me Member	14-Jul-2020 21:21        not_me About Contact  Quote this Post!
x 0   x 0  Alert Admin	U have wind sound? easywin      ( Date: 14-Jul-2020 21:20) Posted: I think we shall hear some good news tomorrow morning before market reopens
Useful To Me  Not Useful To Me
easywin Supreme	14-Jul-2020 21:20        easywin About Contact  Quote this Post!
x 0   x 0  Alert Admin	I think we shall hear some good news tomorrow morning before market reopens
Useful To Me  Not Useful To Me
not_me Member	14-Jul-2020 21:20        not_me About Contact  Quote this Post!
x 0   x 0  Alert Admin	Yea it needs to at least have trading unhalt
Useful To Me  Not Useful To Me
andrewliuyj Member	14-Jul-2020 21:18        andrewliuyj About Contact  Quote this Post!
x 0   x 0  Alert Admin	To be frank this is the second stock I bought...So lucky kena halt... but learn so much from this case also... Hopefully tomorrow last day they will lift it...finger cross
Useful To Me  Not Useful To Me
watashievil Master	14-Jul-2020 21:12        watashievil About Contact  Quote this Post!
x 0   x 0  Alert Admin	Same sentiment bro, i kanna before from such counters hope someone had warned when i was a newbie. For some reason i feel this counter certain aspects reminds me of Yuuzoo counter.  just feel some red flags are showing. still hope it can fly up so bros here can huat big big and exit. nott1965      ( Date: 14-Jul-2020 20:17) Posted: I am not an expert in medical. But in my 25 years of trading experience, I have seen companies that are sound and transparent, who take shareholders as long term stakeholders and companies and directors that are just out to scam investors. I too have my hits and misses. I am just sharing my observations, as anyone is in this forum are here for stanleytay      ( Date: 14-Jul-2020 20:06) Posted: You seem like an expert in medical stocks.. i see you in medtec too. If so, you should be able to see Biolidics and Clearbridge are still laggards compared to medtec, UG or riverstone... Like it or not, medical theme will dominate markets this year. Futhermore, Biolidics high is 0.88.. even at 0.52 now.. its still reasonably ok. Take a chill pill .. its funny people keep painting negative view on it.. at 0.3.. and now
Useful To Me  Not Useful To Me

                                                         First   < Newer   1801-1820 of 4174   Older>   Last